Originally published by our sister publication Clinical Oncology News
In patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer, switching part of first-line treatment from an aromatase inhibitor (AI) to camizestrant (AstraZeneca) if an ESR1 mutation is detected before disease progression, while continuing with a CDK4/6 inhibitor, can slow cancer growth, extend the benefit of first-line therapy and improve quality of life. This conclusion comes from the SERENA-6 study